{"id":4004,"date":"2018-03-16T08:56:56","date_gmt":"2018-03-16T12:56:56","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=4004"},"modified":"2018-03-16T08:56:56","modified_gmt":"2018-03-16T12:56:56","slug":"polypid-ltd-ipo-preview-poly","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/polypid-ltd-ipo-preview-poly\/","title":{"rendered":"PolyPid Ltd. #IPO Preview ($POLY)"},"content":{"rendered":"

\"PolyPid\"<\/a><\/p>\n

Company: PolyPid Ltd.<\/strong>
\nSymbol: POLY
\nDescription: They are a clinical-stage pharmaceutical company focused on developing and commercializing novel, locally administered therapies using their transformational PLEX (Polymer-Lipid Encapsulation matriX) technology.
\nShares: 3.33 million
\nPrice Range: $21.00-$24.00
\nTrade Date: 3\/23
\nUnderwriter(s): Goldman Sachs, Cowen
\nCo-Manager(s): Cantor, Raymond James, Oppenheimer & Co.
\nTerms Added: 3-14-18<\/p>\n

Link to S-1\/A Prospectus<\/a><\/strong><\/p>\n

Link to Retail Roadshow<\/a><\/strong><\/p>\n

Business<\/strong>: They are a clinical-stage pharmaceutical company focused on developing and commercializing novel, locally administered therapies using their transformational PLEX (Polymer-Lipid Encapsulation matriX) technology.<\/p>\n

They are initially focused on the development of their lead product candidate, D-PLEX100, for the prevention of surgical site infections, or SSIs, in bone and soft tissue. They recently reported interim results from their fully-enrolled Phase 1b\/2 clinical trial of D-PLEX100 for the prevention of sternal SSIs after cardiac surgery. During the three-month period after treatment, they observed no sternal wound infections in any of the patients treated with D-PLEX100 in combination with the standard of care. In contrast, they observed a 4.5% infection rate in the control group of patients who received the standard of care alone.<\/p>\n

\"Poly.Drugs\"<\/a><\/p>\n

Insider Buying: <\/strong>Certain of our existing shareholders have indicated an interest in purchasing up to an aggregate of $19.5 million in ordinary shares in this offering at the initial public offering price per share.
\n<\/strong><\/p>\n

Collaboration:<\/strong> They are developing D-PLEX500, formerly known as BonyPid-500, with our collaborator, MIS Implants Technologies Ltd., a subsidiary of Dentsply Sirona Inc., for use in periodontal and oral\/maxillofacial surgeries to treat peri-implantitis, a destructive inflammatory process affecting the soft and bone tissues surrounding dental implants.<\/p>\n

Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/p>\n

IPO Boutique subscription clients receive daily updates on this critical information.<\/span><\/a><\/p>\n

Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0track record<\/span><\/a>\u00a0with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance<\/a>\u00a0to showcase the value of IPO Boutique’s service.<\/p>\n

Indicate with confidence,\u00a0<\/b>SUBSCRIBE<\/b><\/a>\u00a0today.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

Company: PolyPid Ltd. Symbol: POLY Description: They are a clinical-stage pharmaceutical company focused on developing and commercializing novel, locally administered therapies using their transformational PLEX (Polymer-Lipid Encapsulation matriX) technology. Shares: 3.33 million Price Range: $21.00-$24.00 Trade Date: 3\/23 Underwriter(s): Goldman Sachs, Cowen Co-Manager(s): Cantor, Raymond James, Oppenheimer & Co. Terms Added: 3-14-18 Link to S-1\/A[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[1483],"class_list":["post-4004","post","type-post","status-publish","format-standard","hentry","category-ipo","tag-poly"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=4004"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4004\/revisions"}],"predecessor-version":[{"id":4007,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4004\/revisions\/4007"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=4004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=4004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=4004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}